Should blood transfusion be individualised? We are not sure

Citation for published version:
Docherty, A & Walsh, T 2015, 'Should blood transfusion be individualised? We are not sure' Intensive Care Medicine. DOI: 10.1007/s00134-015-4034-4

Digital Object Identifier (DOI):
10.1007/s00134-015-4034-4

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Intensive Care Medicine

Publisher Rights Statement:
This the author's final peer-reviewed manuscript as accepted for publication. The final publication is available at Springer via http://link.springer.com/article/10.1007%2Fs00134-015-4034-4

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
SHOULD BLOOD TRANSFUSION BE INDIVIDUALISED: NOT SURE?

Annemarie Docherty FRCA
Annemarie.Docherty@ed.ac.uk

Timothy S Walsh MD*
Timothy.walsh@ed.ac.uk

*Corresponding author

Anaesthetics, Critical Care and Pain Medicine
Edinburgh University,
Room S8208, 2nd Floor
Royal Infirmary of Edinburgh
51 Little France Crescent
Edinburgh EH16 4SA
0131 242 6395

The authors have no relevant conflicts of interest
We think the evidence supports a restrictive blood transfusion threshold using a haemoglobin concentration (Hb) trigger of 70 g/L in younger, less sick patients in ICUs, especially those without co-existing cardiorespiratory co-morbidity[1, 2]. More liberal transfusion could increase important complications without clinical benefit[3]. In addition, red blood cells are expensive and no trials have demonstrated their cost-effectiveness. Unfortunately, many of our patients are sick, older, and have cardiorespiratory co-morbidity. It is these patients in whom we think individualised transfusion threshold decisions may be needed.

**Physiological arguments against a blanket restrictive Hb trigger**

There is biological plausibility for maintaining higher Hb levels, and by inference, higher oxygen delivery in higher risk patients, such as those with cardiovascular disease and acute severe sepsis. Specifically, the frequent presence of both tachycardia and hypotension in the critically ill, the requirement for catecholamines that increase myocardial work, and the high coronary oxygen extraction ratio, support the argument for higher Hb values in the presence of coronary disease. Coronary oxygen supply-demand imbalance may result in “type II” myocardial infarction or injury. Troponin release is prevalent in the critically ill, and is associated with higher mortality[4, 5].

In sepsis, oxygen supply-demand imbalances may occur regionally, with arteriovenous shunting, resulting in a hypoxaemic microcirculation despite global haemodynamics appearing relatively normal[6, 7]. Red blood cell transfusion may improve oxygen content and availability by recruiting the microcirculation[8]. Many septic patients have cardiovascular co-morbidity, raising the possibility of a “double hit” from severe anaemia in this population. Is a transfusion trigger of 70g/L really safe for all of these cases?

**What does the high quality evidence tell us?**

The FOCUS trial [9] enrolled elderly patients with cardiovascular disease undergoing hip surgery and found no difference in a composite outcome of mortality or inability to walk independently at 60
days (OR liberal-strategy 1.01, 95% CI 0.84 to 1.22). This high quality trial is correctly quoted as evidence that restrictive transfusion practice is safe, but *how* restrictive? The mean (SD) restrictive Hb trigger was 79 (6) g/L and most patients were only exposed to Hb values <90g/L for <3 days. In fact the restrictive arm used individualised triggers based on patients’ symptoms and signs. FOCUS is therefore not strong evidence that 70g/L is “the new norm” for these patients.

The TRICC and TRISS trials are the highest quality evidence in the critically ill, and both used a restrictive Hb trigger of 70g/L[1, 2]. Both reported underpowered cardiovascular and/or ischaemic heart disease sub-group analyses; these showed (non-significant) point estimates that favoured *liberal* practice (TRICC: ARR 4.0%, 95% CI -6.9 to 14.9; TRISS: RR 1.08, 95% CI 0.75 to 1.40).

The median time to recruitment for TRISS was 21 hours after ICU admission, and 14 hours for TRICC, and in a smaller trial of older patients the delay was 96 hours[10]. This excluded the early period of critical illness when arguably the oxygen supply-demand balance may be most deranged. The recent early goal-directed trials in sepsis (ProCESS, ARISE and PROMISE), which included the use of red cell transfusions when the Hb was <100g/L and ScVO₂ <70%, found no outcome benefit overall[11], but relatively few patients triggered the blood transfusion part of the algorithm. It also seems unlikely that many patients had Hb<70g/L during the intervention period. These trials were underpowered for patients with low ScVO₂ *and* low Hb and, importantly, for patient sub-groups with comorbidity such as cardiac disease. The possibility of differential, potentially opposite, effects from fixed interventions in heterogeneous critically ill populations has been illustrated in relation to transfusion[12] (Figure 1). We are uncertain, therefore, that we have strong evidence that a fixed 70g/L Hb trigger is safest for all patients.

**Are we ready for precision medicine in relation to transfusion?**

Mortality is not necessarily the best endpoint for blood transfusion trials in critically ill patients. Clinically important differences may occur that do not translate into mortality differences, or are undetectable without very large sample sizes. This is particularly relevant in critical care where
populations are heterogeneous in terms of comorbidity and acute pathology, and where multiple factors influence the risk of death. In addition to this, anaemia persists in many patients after critical illness[13], and may contribute to the post-ICU syndrome that we are only starting to understand. There is a strong association between transfusion and quality of life in chronic anaemia syndromes[14]; the same might be true in recovering critically ill patients.

At present available methods for measuring cellular, tissue, or organ oxygenation status lack sensitivity and specificity. Perhaps the way forward is to explore novel measures of end organ perfusion to guide transfusion decisions. In relation to the heart, cardiac specific enzymes such as troponin I or MyC (Cardiac myosin binding protein C) may quantify myocardial damage; similarly continuous ECG monitoring could detect the ischaemic burden placed on the heart. Myocardial infarction or injury seems an especially relevant endpoint for patients with cardiovascular disease. The diagnosis of myocardial infarction in the context of critical illness is often subjective, and understanding what levels of biochemically quantified injury are important could lead to future “precision medicine” trials exploring whether interventions such as blood transfusion can modify these outcomes.

**Conclusion**

As is often the case there is common ground in the debate. We agree the evidence supports a default Hb trigger of 70 g/L for younger patients and those without cardiovascular disease (acute or chronic). For critically ill older patients, especially those with cardiac disease, we agree the general approach should be restrictive but are not sure that the evidence supports a “new norm” of 70g/L for all. We are not alone. An analysis of transfusion triggers in the international ABLE trial showed substantial variation, with ischaemic heart disease modifying behaviour[15]. Future studies need to develop strategies to inform precision medicine approaches that can be tested in trials in defined populations. This may enable evidence-based individualised transfusion therapy. Until then we will continue to require clinical judgement.
References


Legend for Figure 1:

The effect of transfusion strategy on mortality is dependent on the presence or absence prerandomization of ischaemic heart disease. In the TRICC transfusion trigger trial[1], the effects of transfusion thresholds on 30-day mortality were significantly different and opposite depending on the presence or absence prerandomization of ischaemic heart disease (Breslow-Day test; p = .03). In patients with ischaemic heart disease (n = 257), the use of a restrictive transfusion strategy increased mortality compared with the use of a liberal strategy. In patients without ischaemic heart disease (n = 581), the use of a restrictive transfusion strategy decreased mortality compared with the use of a liberal strategy. For this analysis, data from the original and subsequent publications were combined. Reproduced with permission from Deans et al[12].